103 related articles for article (PubMed ID: 1517145)
1. Potentiation by tumor necrosis factor of mitoxantrone cytotoxicity to human ovarian cancer cell lines.
Russo P; Parodi S; Billi G; Oliva C; Venturini M; Noviello E; Conte P
Jpn J Cancer Res; 1992 Jul; 83(7):684-7. PubMed ID: 1517145
[TBL] [Abstract][Full Text] [Related]
2. Effect of recombinant human tumor necrosis factor on A2774 human ovarian cancer cell line: potentiation of mitoxantrone cytotoxicity.
Vigani A; Chiara S; Miglietta L; Repetto L; Conte PF; Cimoli G; Morelli L; Billi G; Parodi S; Russo P
Gynecol Oncol; 1991 Apr; 41(1):52-5. PubMed ID: 2026360
[TBL] [Abstract][Full Text] [Related]
3. Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3.
Cimoli G; Valenti M; Parodi S; Mazzoni A; De Sessa F; Conte P; Russo P
Oncol Res; 1993; 5(8):311-23. PubMed ID: 8012063
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of tumour necrosis factor-mediated cell killing by VP16 on human ovarian cancer cell lines. In vitro results and clinical implications.
Valenti M; Cimoli G; Parodi S; Mariani GL; Venturini M; Conte P; Russo P
Eur J Cancer; 1993; 29A(8):1157-61. PubMed ID: 8518027
[TBL] [Abstract][Full Text] [Related]
5. Augmentation of antineoplastic effects by the combination of recombinant human tumor necrosis factor and mitoxantrone on primary culture of human ovarian cancer cells.
Cimoli G; Valenti M; Venturini M; Conte P; Russo P
Anticancer Res; 1992; 12(5):1411-4. PubMed ID: 1444198
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation.
Orengo G; Noviello E; Cimoli G; Pagnan G; Parodi S; Venturini M; Conte P; Schenone F; Conzi G; Russo P
Jpn J Cancer Res; 1992 Nov; 83(11):1132-6. PubMed ID: 1336489
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor and cytotoxic agents. Effect on squamous carcinoma lines.
Gapany M; Dawson DE; Schriever C; Burgess R; Gipple JR; Riggs CE
Arch Otolaryngol Head Neck Surg; 1990 Apr; 116(4):436-9. PubMed ID: 2317326
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of TNF-mediated cell killing by mitoxantrone. Relationship to DNA single-strand break formation.
Valenti M; Cimoli G; Mariani GL; Conte PF; Parodi S; Russo P
Biochem Pharmacol; 1993 Oct; 46(7):1199-206. PubMed ID: 8216370
[TBL] [Abstract][Full Text] [Related]
9. Tumour necrosis factor enhances the therapeutic effect of mitoxantrone in human ovarian cancer xenograft.
Noviello E; Cimoli G; Cosimi A; Allievi E; Galletti P; Parodi S; Russo P
Cytokine; 1996 Apr; 8(4):330-3. PubMed ID: 9162224
[TBL] [Abstract][Full Text] [Related]
10. Circumvention of atypical multidrug resistance with tumor necrosis factor.
Cimoli G; Valenti M; Parodi S; De Sessa F; Russo P
Jpn J Cancer Res; 1994 Feb; 85(2):135-8. PubMed ID: 8144394
[TBL] [Abstract][Full Text] [Related]
11. A rapid in vitro cytotoxicity assay for the detection of tumor necrosis factor on human BT-20 cells.
Yen J; Kramer SM
J Immunother (1991); 1991 Jun; 10(3):174-81. PubMed ID: 1868041
[TBL] [Abstract][Full Text] [Related]
12. Synergistic cytotoxic effects of recombinant human tumor necrosis factor and Etoposide (VP16) or Doxorubicin on A2774 human epithelial ovarian cancer cell line.
Billi G; Venturini M; Piccini D; Parodi S; Rosso R; Conte PF; Russo P
Int J Gynecol Cancer; 1992 May; 2(3):147-151. PubMed ID: 11576250
[TBL] [Abstract][Full Text] [Related]
13. Effect of recombinant human TNF on human ovarian cancer cell lines.
Vigani A; Miglietta L; Chiara S; Repetto L; Pichi E; Cimoli G; Morelli L; Poggi L; Billi G; Parodi S
Boll Soc Ital Biol Sper; 1990 Jun; 66(6):537-42. PubMed ID: 2257120
[TBL] [Abstract][Full Text] [Related]
14. Endogenous tumor necrosis factor enhances topoisomerase II inhibitors activity in human ovarian cancer cell lines.
Debernardis D; Stanzione S; Ottoboni C; Clerico L; Mancuso T; Parodi S; Russo P
J Pharmacol Exp Ther; 1996 Oct; 279(1):84-90. PubMed ID: 8858979
[TBL] [Abstract][Full Text] [Related]
15. Modulation of the growth of transformed cells by human tumor necrosis factor-alpha and interferon-gamma.
Lewis GD; Aggarwal BB; Eessalu TE; Sugarman BJ; Shepard HM
Cancer Res; 1987 Oct; 47(20):5382-5. PubMed ID: 2820567
[TBL] [Abstract][Full Text] [Related]
16. Effect of recombinant human tumor necrosis factor on human nasopharyngeal carcinoma cell line in vitro.
Ha DK; Lau WH
Cancer Lett; 1988 Aug; 41(2):217-24. PubMed ID: 3401845
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor and chemotherapeutic agents. Potentiation of cytotoxicity with interferon gamma.
Dawson DE; Gapany M; Burgess RC; Boesen PV; Headley DB
Arch Otolaryngol Head Neck Surg; 1992 Nov; 118(11):1168-71. PubMed ID: 1418895
[TBL] [Abstract][Full Text] [Related]
18. HPV16-E6 enhances mitoxantrone sensitivity in a human ovarian cancer line: an isolated instance or a trend?
Cimoli G; Valenti M; Ottoboni C; Parodi S
Int J Oncol; 2001 Apr; 18(4):759-65. PubMed ID: 11251171
[TBL] [Abstract][Full Text] [Related]
19. Activation of programmed cell death by recombinant human tumor necrosis factor plus topoisomerase II-targeted drugs in L929 tumor cells.
Kyprianou N; Alexander RB; Isaacs JT
J Natl Cancer Inst; 1991 Mar; 83(5):346-50. PubMed ID: 1847434
[TBL] [Abstract][Full Text] [Related]
20. Effects of tumor necrosis factor, alone or in combination with topoisomerase-II-targeted drugs, on human lung cancer cell lines.
Giaccone G; Kadoyama C; Maneckjee R; Venzon D; Alexander RB; Gazdar AF
Int J Cancer; 1990 Aug; 46(2):326-9. PubMed ID: 2166714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
